1 / 33

Evaluating the Patient With Abnormal Liver Tests-2

Evaluating the Patient With Abnormal Liver Tests-2. פרופ ' צבי אקרמן מבית חולים הדסה הר הצופים. Imaging studies. Abdominal Ultrasound with Doppler of hepatic and portal veins Abdominal MRCP Upper endoscopy (EGD) Liver biopsy Non Invasive Tests for Fibrosis. Imaging studies-1.

rudyard-mathis
Télécharger la présentation

Evaluating the Patient With Abnormal Liver Tests-2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Evaluating the Patient With Abnormal Liver Tests-2 פרופ' צבי אקרמן מבית חולים הדסה הר הצופים

  2. Imaging studies • Abdominal Ultrasound with Doppler of hepatic and portal veins • Abdominal MRCP • Upper endoscopy (EGD) • Liver biopsy • Non Invasive Tests for Fibrosis

  3. Imaging studies-1 • Abdominal Ultrasound with Doppler of hepatic and portal veins-1 • Abdominal ultrasound is helpful in the evaluation of patients with cirrhosis. • It may reveal a shrunken, nodular liver suggestive of cirrhosis.

  4. Imaging studies-1a • The liver may appear echogenic if excessive fat has infiltrated the liver as in NAFLD (nonalcoholic fatty liver disease). • It is sensitive for the detection of small to moderate amounts of ascites. • It can be used to screen for liver masses which may suggest the presence of hepatocellular carcinoma.

  5. Imaging studies-2 • Abdominal Ultrasound with Doppler of hepatic and portal veins-2 • The use of Doppler ultrasonography can provide information about the hepatic and portal veins such as portal vein thrombosis. • Because it is relatively inexpensive, and widely available, ultrasonography is the preferred initial imaging modality in patients with cirrhosis.

  6. Imaging studies-3 • Abdominal MRCP • MRI is not indicated in every evaluation of liver disease , only in cases where specific bile duct pathology is suspected. • It is expensive and ‘simple”information can be obtained with ultrasonography.

  7. Imaging studies-4 • Upper endoscopy (EGD) • Upper endoscopy is useful in the diagnosis of esophageal varices, a finding seen with portal hypertension. • In cirrhotic patients, it is useful to document the presence of varices so prophylactic measures can be instituted to decrease the risk of bleeding.

  8. Imaging studies-3

  9. Imaging studies-3

  10. Imaging studies • Abdominal Ultrasound with Doppler of hepatic and portal veins • Abdominal MRCP • Upper endoscopy (EGD) • Liver fibrosis Assessment :Liver biopsy • Liver fibrosis Assessment :Non Invasive Tests for Fibrosis

  11. Liver Biopsy • HepaticInjury : • necrotico-inflammatoryactivity, • fibrosis, • steatosis, • biliarylesions, vascularlesions • Fibrosis scores • ( METAVIR, Knodell , Ishak,…) •  Invasive procedure • morbidity : 0.3 to 0.6% • mortality : 0 to 0.05% • Cost : approximately 4000 NIS ( without complications)

  12. F1 F2 F4

  13. F1 F4

  14. Imaging studies

  15. BioMarkers of liver injury • Markers of Fibrosis • Scores of Fibrosis

  16. How must be an ideal marker of liver Fibrosis? • Specific to the Liver • Independant to metabolic dysfunction • Easy to perform • Sensitivity to detect the different stages of liver fibrosis • Can reliably assess the efficacy of antifibrotic treatment • Can be used whatever the etiology of chonic liver fibrosis • Non influenced by extra-hepatic factors

  17. Liver Injury Alpha2Macroglobulin Total Bilirubin Gamma GT ALT Apolipoprotein A1 Haptoglobin In Serum: FibroTest In Situ Fibrotic Matrix Activated Stellate Cells

  18. Multicenter Independant Validation Halfon, Am J Gastroenterol 2006 FibroTest 1.00 n=519 0.90 0.80 0.70 0.60 0.50 0.40 0.30 0.20 0.10 0.00 0 1 2 3 4 METAVIR Fibrosis Stage

  19. FibroTest: fibrosis marker in otherchronicliverdiseases (n=2,706) Myers et al 2003 Poynard et al 2004 Myers et al 2003 Ratziu et al 2004 Naveau et al 2005

  20. LONGITUDINAL STUDIES The Fibrotest was found to predict the evolution of HCV patients towards cirrhosis better than liver biopsy after 5 years of follow-up Ngo ClinChem 2006

  21. Progression of liver fibrosis F METAVIR Rapid Intermediate Slow fibroser Duration in years Poynard et al

  22. Abnormal Liver Test Results: Points for Clinical Practice • Abnormal liver test results will be identified in 8%-20% of patients during clinical care. • Most patients with abnormal liver test results should have additional evaluation. A referral to the gastroenterologist may be needed. • A careful history and physical examination frequently provide the diagnosis, obviating the need for invasive testing. • If there are signs or symptoms of chronic liver disease, considering the patient's age may assist in the diagnosis. • Isolated elevation of GGT occurs and a cause may not be identified.

  23. CON-Abnormal Liver Test Results: Points for Clinical Practice • The presence of multiple abnormal test results makes significant liver disease more likely. • Aminotransferase, alkaline phosphatase, and GGT levels can be elevated from causes other than liver disease. • Persisting abnormalities of aminotransferases or enzymes of cholestasis should be further evaluated because up to two thirds will have a diagnosis requiring follow-up or intervention. • Supplemental testing with additional laboratory tests, ultrasonography, or magnetic resonance cholangiography should be considered when the diagnosis is unclear or confirmation of liver disease diagnosis is required.

  24. תודה רבה על ההקשבה

More Related